Program
PRMT5 Inhibitor SH3765
Also written as “SH3765+Fulvestrant” and “SH3765 tablet”.
Its studies are mostly in Breast Neoplasms, led by Nanjing Sanhome Pharmaceutical.
Furthest: phase 1, since Aug 18, 20212 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing Sanhome Pharmaceutical | 21 open or running | phase 1since Aug 18, 2021 | Aug 18, 2021 | Jun 30, 2027phase 1 · NCT07557004 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 18, 2021First study: phase 1 study in Advanced Malignant TumorFirst studyNCT05015309 · 40 enrolled · China
- Apr 15, 2026Phase 1 study in HR+ / HER2- Advanced Breast CancerNCT07557004 · 30 enrolled · China
Ahead
- Jun 30, 2027Primary completion: phase 1 study in HR+ / HER2- Advanced Breast CancerNCT07557004
TargetBeta
PRMT5 →read by rule
“An orally bioavailable inhibitor of protein arginine methyltransferase 5 (PRMT5), ”NCIt, by rule
Other programs on PRMT5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| navlimetostat | Bristol-Myers Squibb | phase 3 | 10 |
| PRMT5 Inhibitor AZD3470 | AstraZeneca | phase 2 | 2 |
| JBI-778rule | jubilant-therapeutics-india-limited | phase 2 | 2 |
| PRMT5 Inhibitor TNG456rule | tango-therapeutics-inc | phase 2 | 1 |
| PRMT5 Inhibitor BAY 3713372rule | Bayer | phase 2 | 1 |
| onametostatrule | Johnson & Johnson | phase 1 | 2 |
| PRMT5 Inhibitor BGB-58067rule | BeOne Medicines | phase 1 | 2 |
| PRMT5 Inhibitor IDE892rule | ideaya-biosciences | phase 1 | 1 |
| PEP08rule | pharmaengine | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07557004HR+ / HER2- Advanced Breast Cancer · China | 1 | Active, not recruiting | Jun 30, 2027 | 30 |
| NCT05015309Advanced Malignant Tumor · China | 1 | UNKNOWN | Mar 2023 | 40 |
How it is read
Names in the registry
- “SH3765+Fulvestrant”, 1 entry
- “SH3765 tablet”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.